Frequency of prediabetes in individuals with increased adiposity and metabolically healthy or unhealthy phenotypes.
estimated glucose disposal rate
impaired fasting glucose
impaired glucose tolerance
insulin‐resistance
metabolically healthy obesity
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
08 May 2024
08 May 2024
Historique:
revised:
21
04
2024
received:
01
03
2024
accepted:
22
04
2024
medline:
9
5
2024
pubmed:
9
5
2024
entrez:
9
5
2024
Statut:
aheadofprint
Résumé
To utilize the estimated glucose disposal rate (eGDR) index of insulin sensitivity, which is based on readily available clinical variables, namely, waist circumference, hypertension and glycated haemoglobin, to discriminate between metabolically healthy and unhealthy phenotypes, and to determine the prevalence of prediabetic conditions. Non-diabetic individuals (n = 2201) were stratified into quartiles of insulin sensitivity based on eGDR index. Individuals in the upper quartiles of eGDR were defined as having metabolically healthy normal weight (MHNW), metabolically healthy overweight (MHOW) or metabolically healthy obesity (MHO) according to their body mass index, while those in the lower quartiles were classified as having metabolically unhealthy normal weight (MUNW), metabolically unhealthy overweight (MUOW) and metabolically unhealthy obesity (MUO), respectively. The frequency of impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and IFG + IGT status was comparable among the MHNW, MHOW and MHO groups, while it increased from those with MUNW status towards those with MUOW and MUO status. As compared with participants with MHNW, the odds ratio of having IFG, IGT, or IFG + IGT was significantly higher in participants with MUOW and MUO but not in those with MUNW, MHOW and MHO, respectively. A metabolically healthy phenotype is associated with lower frequency of IFG, IGT, and IFG + IGT status across all body weight categories.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Sapienza Università di Roma
ID : RM1201728887461F
Organisme : European Foundation for the Study of Diabetes
ID : EFSD/Lilly Young Investigator Research Award
Organisme : Ministero dell'Università e della Ricerca
ID : 2020N5WK98_005
Organisme : Società Italiana di Medicina Interna Mario Condorelli award
Informations de copyright
© 2024 John Wiley & Sons Ltd.
Références
NCD Risk Factor Collaboration (NCD‐RisC). Trends in adult body mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population‐based measurement studies with 19.2 million participants. Lancet. 2016;387:1377‐1396.
Rosen ED, Spiegelman BM. What we talk about when we talk about fat. Cell. 2014;156:20‐44.
Scherer PE. The many secret lives of adipocytes: implications for diabetes. Diabetologia. 2019;62:223‐232.
Karelis AD, St‐Pierre DH, Conus F, Rabasa‐Lhoret R, Poehlman ET. Metabolic and body composition factors in subgroups of obesity: what do we know? J Clin Endocrinol Metab. 2004;89:2569‐2575.
Stefan N, Häring H‐U, Hu FB, Schulze MB. Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol. 2013;1:152‐162.
Schulze MB. Metabolic health in normal‐weight and obese individuals. Diabetologia. 2019;62(4):558‐566.
Smith GI, Mittendorfer B, Klein S. Metabolically healthy obesity: facts and fantasies. J Clin Invest. 2019;129(10):3978‐3989.
Stefan N. Causes, consequences, and treatment of metabolically unhealthy fat distribution. Lancet Diabetes Endocrinol. 2020;8:616‐627.
Bluher M. Metabolically healthy obesity. Endocr Rev. 2020;41(3):1‐16.
Despres JP. Taking a closer look at metabolically healthy obesity. Nat Rev Endocrinol. 2022;18(3):131‐132.
Karelis AD, Faraj M, Bastard JP, et al. The metabolically healthy but obese individual presents a favorable inflammation profile. J Clin Endocrinol Metab. 2005;90:4145e50.
Marini MA, Succurro E, Frontoni S, et al. Metabolically healthy but obese women have an intermediate cardiovascular risk profile between healthy nonobese women and obese insulin‐resistant women. Diabetes Care. 2007;30(8):2145‐2147.
Stefan N, Kantartzis K, Machann J, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med. 2008;168:1609‐1616.
Succurro E, Marini MA, Frontoni S, et al. Insulin secretion in metabolically obese, but normal weight, and in metabolically healthy but obese individuals. Obesity. 2008;16:1881‐1886.
Sesti G, Succurro E, Arturi F, et al. IGF‐1 levels link estimated glomerular filtration rate to insulin resistance in obesity: a study in obese, but metabolically healthy, subjects and obese, insulin‐resistant subjects. Nutr Metab Cardiovasc Dis. 2011;21:933‐940.
Rey‐López JP, de Rezende LF, Pastor‐Valero M, Tess BH. The prevalence of metabolically healthy obesity: a systematic review and critical evaluation of the definitions used. Obes Rev. 2014;15:781‐790.
Stefan N, Schulze MB. Metabolic health and cardiometabolic risk clusters: implications for prediction, prevention, and treatment. Lancet Diabetes Endocrinol. 2023;11(6):426‐440.
Bell JA, Kivimaki M, Hamer M. Metabolically healthy obesity and risk of incident type 2 diabetes: a meta‐analysis of prospective cohort studies. Obes Rev. 2014;15(6):504‐515.
Lotta LA, Abbasi A, Sharp SJ, et al. Definitions of metabolic health and risk of future type 2 diabetes in BMI categories: a systematic review and network meta‐analysis. Diabetes Care. 2015;38(11):2177‐2187.
Tajik S, Mirzababaei A, Ghaedi E, Kord‐Varkaneh H, Mirzaei K. Risk of type 2 diabetes in metabolically healthy people in different categories of body mass index: an updated network meta‐analysis of prospective cohort studies. J Cardiovasc Thorac Res. 2019;11(4):254‐263.
Richter B, Hemmingsen B, Metzendorf MI, Takwoingi Y. Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia. Cochrane Database Syst Rev. 2018;10:CD012661.
Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; world heart federation; international atherosclerosis society; and International Association for the Study of obesity. Circulation. 2009;120(16):1640‐1645.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta‐cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412‐419.
Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22(9):1462‐1470.
Williams KV, Erbey JR, Becker D, Arslanian S, Orchard TJ. Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes. 2000;49(4):626‐632.
Nyström T, Holzmann MJ, Eliasson B, Svensson A‐M, Sartipy U. Estimated glucose disposal rate predicts mortality in adults with type 1 diabetes. Diabetes Obes Metab. 2018;20(3):556‐563.
Zabala A, Darsalia V, Lind M, et al. Estimated glucose disposal rate and risk of stroke and mortality in type 2 diabetes: a nationwide cohort study. Cardiovasc Diabetol. 2021;20:202.
Laakso M, Zilinskaite J, Hansen T, et al. Insulin sensitivity, insulin release and glucagon‐like peptide‐1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study. Diabetologia. 2008;51:502‐511.
Cefalo CMA, Succurro E, Riccio A, et al. Low‐density lipoprotein cholesterol levels are associated with first‐phase insulin release. Diabetes Res Clin Pract. 2023;199:110633.
Succurro E, Marini MA, Riccio A, et al. Sex‐differences in insulin sensitivity and insulin secretion in subjects with impaired fasting glucose and impaired glucose tolerance. Diabetes Res Clin Pract. 2022;194:110185.
Succurro E, Miceli S, Fiorentino TV, et al. Sex‐specific differences in left ventricular mass and myocardial energetic efficiency in non‐diabetic, pre‐diabetic and newly diagnosed type 2 diabetic subjects. Cardiovasc Diabetol. 2021;20(1):60.
Riccio A, Mazzanti C, Vero L, et al. Liver fibrosis is associated with an increased risk of non‐fatal myocardial infarction. Eur J Clin Invest. 2023;12:e14061.
Gastaldelli A. Measuring and estimating insulin resistance in clinical and research settings. Obesity (Silver Spring). 2022;30(8):1549‐1563.
American Diabetes Association Professional Practice Committee. Classification and diagnosis of diabetes: standards of Care in Diabetes‐2023. Diabetes Care. 2024;47(suppl. 1):S20‐S42.
Sims A. Are there persons who are obese, but metabolically healthy? Metabolism. 2001;50:1499‐1504.
Brochu M, Tchernof A, Dionne IJ, et al. What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women? J Clin Endocrinol Metab. 2001;86:1020‐1025.
Abdul‐Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta‐cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care. 2006;29(5):1130‐1139.
Stefan N, Cusi K. A global view of the interplay between non‐alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol. 2022;10(4):284‐296.
Stefan N, Schick F, Birkenfeld AL, Häring HU, White MF. The role of hepatokines in NAFLD. Cell Metab. 2023;35(2):236‐252.
Fujihara K, Matsubayashi Y, Yamamoto M, et al. Impact of body mass index and metabolic phenotypes on coronary artery disease according to glucose tolerance status. Diabetes Metab. 2017;43(6):543‐546.
Zhang J, Xu Q, Lai F, et al. Joint associations of metabolically healthy abdominal obesity and non‐alcoholic fatty liver disease with prediabetes and diabetes in Chinese adults. BMJ Open Diabetes Res Care. 2021;9(1):e002362.
Lipska KJ, De Rekeneire N, Van Ness PH, et al. Identifying dysglycemic states in older adults: implications of the emerging use of hemoglobin A1c. J Clin Endocrinol Metab. 2010;95:5289‐5295.
Herman WH, Cohen RM. Racial and ethnic differences in the relationship between HbA1c and blood glucose: implications for the diagnosis of diabetes. J Clin Endocrinol Metab. 2012;97:1067‐1072.